Effectiveness of BNT162b2 XBB Vaccine Against XBB and JN.1 Sublineages

Sara Y Tartof; Jeff M Slezak; Laura Puzniak; Timothy B Frankland; Bradley K Ackerson; Luis Jodar; John M McLaughlin

doi:10.1093/ofid/ofae370

Effectiveness of BNT162b2 XBB Vaccine Against XBB and JN.1 Sublineages

Open Forum Infect Dis. 2024 Jul 1;11(7):ofae370. doi: 10.1093/ofid/ofae370. eCollection 2024 Jul.

Authors

Sara Y Tartof¹, Jeff M Slezak¹, Laura Puzniak², Timothy B Frankland³, Bradley K Ackerson⁴, Luis Jodar², John M McLaughlin²

Affiliations

¹ Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
² Global Vaccines and Antivirals, Pfizer Inc, Collegeville, Pennsylvania, USA.
³ Center for Integrated Health Care Research (CIHR), Kaiser Permanente Hawaii, Honolulu, Hawaii, USA.
⁴ Department of Pediatric Infectious Diseases, Southern California Permanente Medical Group, Harbor City, California, USA.

Abstract

We provide updated results (11 October 2023 through 29 February 2024) from our previously conducted test-negative case-control study in Kaiser Permanente Southern California to evaluate sublineage-specific effectiveness of the BNT162b2 XBB1.5-adapted vaccine. Results suggest that XBB1.5-adapted vaccines may have reduced effectiveness against JN.1 versus XBB sublineages.

Keywords: BNT162b2; COVID-19; JN.1; XBB; vaccine effectiveness.